mgb-bp-3
Small moleculeexperimental
Clinical trial activity
2 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02518607)
Timeline
Indications
Mechanism of action
- DNABINDING AGENT
DNA binding agent
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(NC(=O)c2cc(NC(=O)c3ccc(/C=C/c4cnc5ccccc5c4)cc3)cn2C)cc1C(=O)NCCN1CCOCC1- Mol. weight
- 631.74 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL236345 ↗
Also known as
- mgb-bp-3
- mgb-bp-3
- mgb-bp-3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03824795 | Phase 2 | Feb 7, 2019 | MGB Biopharma Limited, Syneos Health |
| NCT02518607 | Phase 1 | Jul 1, 2015 | Analytical Services International Limited, Cambridge Regulatory Services, Hammersmith Medicines Research, Innovate UK, MGB Biopharma Limited, Synlab Services, Viapath |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MGB Biopharma Limited | For profit | 2 | 2 | 2 | 2015 |
| Analytical Services International Limited | For profit | 1 | 0 | 1 | 2015 |
| Cambridge Regulatory Services | For profit | 1 | 0 | 1 | 2015 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2015 |
| Innovate UK | Government | 1 | 0 | 1 | 2015 |
| Syneos Health | For profit | 1 | 0 | 1 | 2019 |
| Synlab Services | For profit | 1 | 0 | 1 | 2015 |
| Viapath | For profit | 1 | 0 | 1 | 2015 |
8 organizations
Page 1 / 1